Title: Bevacizumab
CAS Registry Number: 216974-75-3
CAS Name: Anti-(human vascular endothelial growth factor) immunoglobulin G1 (human-mouse monoclonal rhuMAb-VEGF g1-chain) disulfide with human-mouse monoclonal rhuMAb-VEGF light chain, dimer
Additional Names: rhuMAb-VEGF
Trademarks: Avastin (Genentech)
Literature References: Recombinant humanized monoclonal antibody directed against vascular endothelial growth factor (VEGF). Prepn: L. G. Presta et al., Cancer Res. 57, 4593 (1997); M. Baca et al., WO 9845331 (1998 to Genentech). Biodistribution study: Y. S. Lin et al., J. Pharmacol. Exp. Ther. 288, 371 (1999). Clinical pharmacokinetics: M. S. Gordon et al., J. Clin. Oncol. 19, 843 (2001). Clinical trial in renal cancer: J. C. Yang et al., N. Engl. J. Med. 349, 427 (2003); in combination therapy in colorectal cancer: F. Kabbinavar et al., J. Clin. Oncol. 21, 60 (2003). Symposium on antiangiogenic and antitumor activity: Semin. Oncol. 29, Suppl. 16, 1-18 (2002). Review of development and clinical experience: N. Ferrara et al., Nat. Rev. Drug Disc. 3, 391-400 (2004).
Therap-Cat: Antineoplastic.
Keywords: Antineoplastic; Monoclonal Antibodies. |